Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "opportunistic intestinal pathogens" refers collectively to various microorganisms, including bacteria (e.g., *Clostridioides difficile*, *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*), fungi (e.g., *Candida albicans*), viruses, and parasites, that rarely cause disease in immunocompetent hosts but are capable of causing significant infections in individuals with weakened immune defenses or altered gut environments[2][3][4]. These organisms may be part of the normal intestinal flora or acquired from the environment or healthcare settings, and they become pathogenic ("opportunistic") when host resistance is compromised (due to diseases such as HIV/AIDS, malignancies, transplantation, or broad-spectrum antibiotic use)[1][2][3][4]. The clinical manifestations depend on the specific microorganism and may include diarrhea, colitis, sepsis, or other gastrointestinal symptoms or systemic infections. Prevention and treatment focus on immune support, cautious antimicrobial use, and, when necessary, direct targeting of the causative pathogen with appropriate drugs[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Opportunistic intestinal pathogens.